ADMA Biologics Inc: valuation

ADMANASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$13.79

November 16, 2026Market cap $3.1B

What Ploutos Investor adds for ADMA Biologics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 15 fiscal years, from 2011
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has risen 31% since Nov 4, 2026, when the 10-Q these figures come from was filed ($10.48 then, $13.68 on Nov 13, 2026). The figures date from before that move.10-Q

Valuation today

What the market pays for the company's earnings, cash flow, book value and revenue at $13.79 (November 16, 2026), beside the median of its past fiscal years.

Today's P/B (7.0) is 23% below the median of the chart's 3 years (9.1).

EV / EBIT
13.0
EV / Revenue
6.0
Earnings yield
6.0%
FCF yield
4.3%
Market cap
$3.1B
enterprise value $3.1B
  • 2025
    P/E30.4
  • 2024
    P/E21.2
  • 2023
    P/E–

Each multiple at the closing price of the fiscal year's last trading day and the same year's figures. A year with a loss or negative free cash flow has no P/E or P/FCF. A P/E or P/FCF above 100 is left out: it comes from a year of near-zero earnings or cash flow and says little about the price.

Valuation against its own past

ADMA's P/E, P/FCF and P/B at each year-end price, from 2011 to 2022, 12 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

What today's price assumes

The discounted cash flow model run backwards: not what the company is worth, but the growth the price takes for granted.

For a buyer at $13.79 who wants 9% a year, free cash flow would need to grow by about

+7.2%a year for ten years

at 7% a year
+2.5%
at 9% a year
+7.2%
at 11% a year
+11.2%

Arithmetic on the price, not a forecast. Starts from free cash flow of $133M over the last 12 months and net debt $71M, the same growth each year for ten years, then 2.5% a year forever. Try other numbers in the DCF calculator.

DCF calculator

What is ADMA Biologics worth on your own assumptions?

The DCF calculator opens with the company's figures already filled in from its filings. You set how fast its cash flow grows and the return you ask for, and see the value those assumptions give.

Free cash flow, 12 months
$133M
Net debt
$71M
Shares
222M
FCF, 5-year average a year
–
Revenue, 5-year average a year
+64.6%
Price
$13.79

The full analysis

What do ADMA Biologics's filings show?

The multiples say what the market pays for ADMA Biologics. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ADMA's valuation

Didn't find what you were looking for?

Ask us
What is ADMA's P/E?

ADMA's P/E is 16.8, on earnings per share of $0.77 over the last 12 months.

What is ADMA's P/FCF?

ADMA's P/FCF is 23.0: a market cap of $3.1B over $133M of free cash flow in the last 12 months. Put the other way, a free cash flow yield of 4.3%.

How do I work out what ADMA is worth?

With the DCF calculator: it opens with ADMA Biologics's figures from its filings, you enter your assumptions for growth and the return you ask for, and see the value they give. The company pages give no price target of their own. A full analysis gives a fair-value range, which is an estimate, not a target.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. The estimated fair value, where shown, is our estimate, labelled as one: not a fact, not a score and not a recommendation to buy or sell.